Sutro Biopharma Free Cash Flow (FCF) History (STRO)
Sutro Biopharma reported $11.1M in free cash flow for fiscal 2018, an increase of $51.5M from the previous fiscal year, with a free cash flow margin of 28.96%.
View full Sutro Biopharma company overviewSutro Biopharma free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2018 | 2018-12-31 | $11.1M | $51.5M | — | +28.96% |
| 2017 | 2017-12-31 | −$40.4M | −$22.8M | — | −78.06% |
| 2016 | 2016-12-31 | −$17.5M | — | — | −29.38% |
Sutro Biopharma quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2020 | 2020-03-31 | −$19.5M | −$12.8M | — | −272.61% |
| Q3 2019 | 2019-09-30 | −$16.8M | −$64.0M | — | −136.74% |
| Q2 2019 | 2019-06-30 | −$16.1M | −$2.1M | — | −152.87% |
| Q1 2019 | 2019-03-31 | −$20.4M | −$5.0M | — | −236.66% |
| Q4 2018 | 2018-12-31 | −$6.7M | — | — | −35.28% |
| Q3 2018 | 2018-09-30 | $47.2M | — | — | +602.53% |
| Q2 2018 | 2018-06-30 | −$14.0M | — | — | −245.11% |
| Q1 2018 | 2018-03-31 | −$15.4M | — | — | −265.39% |
Sutro Biopharma free cash flow growth trends
Sutro Biopharma's latest reported quarter, Q1 2020, generated −$19.5M in free cash flow, a decrease of $12.8M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Sutro Biopharma filings at SEC.gov ↗